Enanta Pharmaceuticals, Inc. (ENTA)
$
10.86
+0.23 (2.12%)
Key metrics
Financial statements
Free cash flow per share
-2.0435
Market cap
224.5 Million
Price to sales ratio
3.4636
Debt to equity
2.6123
Current ratio
4.9992
Income quality
0.2520
Average inventory
0
ROE
-0.8902
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Enanta Pharmaceuticals, Inc., founded in 1995 and headquartered in Watertown, Massachusetts, focuses on the discovery and development of small molecule drugs aimed at treating viral infections and liver diseases. The company targets various diseases through its research and development efforts, including respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. In its financial operations, the company reported selling, general, and administrative expenses of $57,850,000.00 indicating its operational overhead costs. The operating expenses amount to $189,326,000.00 encompassing various operational costs incurred during the year. Additionally, the company incurred an income tax expense of -$1,743,000.00 reflecting its obligations to tax authorities. Evaluating operational performance, the EBITDA ratio is -1.55 highlighting the company's operational efficiency. Furthermore, the gross profit stands at $67,635,000.00 showcasing the company's profitability from its core operations. Enanta has a collaborative development agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitors, including paritaprevir and glecaprevir for treating chronic hepatitis C virus. In the investment landscape, the stock is affordable at $7.64 making it an appealing option for budget-conscious investors. However, the stock has a low average trading volume of 672,518.00 indicating lower market activity that might attract investors looking for stability. With a market capitalization of $232,158,097.00 the company is classified as a small-cap player, which often appeals to investors seeking growth opportunities within burgeoning enterprises. Enanta Pharmaceuticals, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches. Moreover, it belongs to the Healthcare sector, driving innovation and growth as it continues to advance its pipeline of drug candidates.
Is Enanta Pharmaceuticals, Inc. (ENTA) a good investment?
Investing in Enanta Pharmaceuticals, Inc. (ENTA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Enanta Pharmaceuticals, Inc. (ENTA)'s stock forecast?
Analysts predict Enanta Pharmaceuticals, Inc. stock to fluctuate between $4.09 (low) and $15.34 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Enanta Pharmaceuticals, Inc.'s market capitalization?
As of 2025-10-30, Enanta Pharmaceuticals, Inc.'s market cap is $232,158,097, based on 21,377,357 outstanding shares.
How does Enanta Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Enanta Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Enanta Pharmaceuticals, Inc. (ENTA) stock?
To buy Enanta Pharmaceuticals, Inc. (ENTA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ENTA. Place an order (Market, Limit, etc.).
What is the best time to invest in Enanta Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Enanta Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $67,635,000 | EPS: -$5.48 | Growth: -14.11%.
Where can I find Enanta Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.enanta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Enanta Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Enanta Pharmaceuticals, Inc. stock?
All-time high: $102 (2021-11-05) | All-time low: $4.09 (2025-04-09).
What are the key trends affecting Enanta Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of custom.
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its comm.
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those with.
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast.
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. “The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Company more than two decades ago, Paul's leadership and generosity of spirit have been at the core of Enan.
zacks.com
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago.
businesswire.com
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV.
See all news
